Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novartis’ Heart Drug Could Save 28,000 US Heart Failure Patients Each Year

XTALKS VITALS NEWS

Heart Failure

According to the researchers in the latest study, if all 2.2 million eligible patients were to use Entresto, the drug could delay or prevent 28,484 deaths, per year.

Share this!

Tweet: Novartis' Entresto could prevent 28,000 #heartfailure deaths in the US each year. http://ctt.ec/bfb8l+Novartis' Entresto could prevent 28,000 heart failure deaths in the US each year.

Tweet: Novartis' Entresto to be more cost-effective compared to the standard of care treatment. http://ctt.ec/sSbm0+Novartis' Entresto to be more cost-effective compared to the standard of care treatment.

June 28, 2016 | by Sarah Massey, M.Sc.

A new study published in the journal, JAMA Cardiology, suggests that Novartis’ Entresto could prevent 28,000 heart failure deaths in the US each year. It’s estimated that 2.7 million patients in the US are affected by a specific type of heart failure – known as heart failure and reduced ejection fraction – and approximately 84 percent of this patient population could be candidates for treatment with Entresto.

An additional study – also published in JAMA Cardiology – found treatment with Entresto to be more cost-effective compared to the standard of care treatment, the angiotensin-converting enzyme (ACE) inhibitor, enalapril. Despite launching the heart drug last year, Novartis has seen slow sales of Entresto. The company hopes that this latest data will help boost Entresto’s market presence.

According to the researchers in the latest study, if all 2.2 million eligible patients were to use Entresto, the drug could delay or prevent 28,484 deaths, per year. Based on the results, the researchers say that putting off treatment with the drug could have “substantial downsides.”



The number of eligible patients was estimated based on the drug’s label restrictions, however the study authors admit that the actual number of ineligible patients could be higher. This, along with the increased costs associated with widespread treatment with Entresto, could change the conclusions reached by the researchers.

An earlier clinical trial sponsored by Novartis, found that Entresto reduced the risk of heart failure-related hospitalizations and death by 20 percent, and lowered overall mortality by 16 percent. Despite initial costs, over a 30-year period, treatment with Entresto has been estimated to be more cost-effective than current treatments.

In an effort to collect further supporting data for the drug, Novartis has expanded their clinical trials of the drug. In the face of increasing generic competition, Novartis is hopeful that the heart drug will help boost revenue.


Keywords: Heart Failure, Heart Drug, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.